Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Comparative Effectiveness of Rivaroxaban Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism (RECENT)

NCT04444804 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04444804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04444804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Comparative Effectiveness of Rivaroxaban Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism (RECENT)
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
July 31, 2020
Completion date
April 30, 2021
Enrollment
22,153 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

venous thromboembolism